Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 4Squamous Intraepithelial Lesions 4Uterine Cervical Dysplasia 2Anus Neoplasms 2Vulvar Neoplasms 1Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1Vaginal Neoplasms 1Recurrence 1Penile Neoplasms 1Papillomavirus Infections 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Squamous Cell Cancer 1HIV Seropositivity 1Anal Canal Carcinoma 1

Interventions

Cisplatin 178Paclitaxel 79Radiotherapy 76Carboplatin 70Brachytherapy 69pembrolizumab 63Bevacizumab 40Gemcitabine 28Radiation 27Topotecan 26Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 25Nivolumab 22Colposcopy 22human papillomavirus vaccine, L1 type 16, 18 21Magnetic Resonance Spectroscopy 21Drug Therapy 20atezolizumab 19Platinum 19Papillomavirus Vaccines 18Radiotherapy, Intensity-Modulated 17Docetaxel 17Taxes 16Cyclophosphamide 16Biopsy 16Early Intervention, Educational 151,2-diaminocyclohexaneplatinum II citrate 15Methods 14Blood Specimen Collection 14fludarabine 13Injections 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Uterine Cervical Neoplasms × VGX-3100 × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

NCT02172911 2021-02-21

A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer

Inovio Pharmaceuticals

Phase 1/2 Completed
10 enrolled 19 charts
Gynecologic

Uterine Cervical Neoplasms

NCT01188850 2018-08-10

Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100

Inovio Pharmaceuticals

Phase 1 Completed
14 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT00685412 2017-09-13

Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3

Inovio Pharmaceuticals

Phase 1 Completed
18 enrolled
Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡